118 related articles for article (PubMed ID: 12867035)
1. Hdm2 recruits a hypoxia-sensitive corepressor to negatively regulate p53-dependent transcription.
Mirnezami AH; Campbell SJ; Darley M; Primrose JN; Johnson PW; Blaydes JP
Curr Biol; 2003 Jul; 13(14):1234-9. PubMed ID: 12867035
[TBL] [Abstract][Full Text] [Related]
2. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway.
Zhang Y; Wolf GW; Bhat K; Jin A; Allio T; Burkhart WA; Xiong Y
Mol Cell Biol; 2003 Dec; 23(23):8902-12. PubMed ID: 14612427
[TBL] [Abstract][Full Text] [Related]
3. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53.
Tao W; Levine AJ
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3077-80. PubMed ID: 10077639
[TBL] [Abstract][Full Text] [Related]
4. MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm.
Phelps M; Phillips A; Darley M; Blaydes JP
J Biol Chem; 2005 Apr; 280(17):16651-8. PubMed ID: 15723837
[TBL] [Abstract][Full Text] [Related]
5. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
6. Complementary quantitative proteomics reveals that transcription factor AP-4 mediates E-box-dependent complex formation for transcriptional repression of HDM2.
Ku WC; Chiu SK; Chen YJ; Huang HH; Wu WG; Chen YJ
Mol Cell Proteomics; 2009 Sep; 8(9):2034-50. PubMed ID: 19505873
[TBL] [Abstract][Full Text] [Related]
7. Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation.
Migliorini D; Danovi D; Colombo E; Carbone R; Pelicci PG; Marine JC
J Biol Chem; 2002 Mar; 277(9):7318-23. PubMed ID: 11744695
[TBL] [Abstract][Full Text] [Related]
8. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.
Roth J; Dobbelstein M; Freedman DA; Shenk T; Levine AJ
EMBO J; 1998 Jan; 17(2):554-64. PubMed ID: 9430646
[TBL] [Abstract][Full Text] [Related]
9. Defining the molecular basis of Arf and Hdm2 interactions.
Bothner B; Lewis WS; DiGiammarino EL; Weber JD; Bothner SJ; Kriwacki RW
J Mol Biol; 2001 Nov; 314(2):263-77. PubMed ID: 11718560
[TBL] [Abstract][Full Text] [Related]
10. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation.
Wang C; Ivanov A; Chen L; Fredericks WJ; Seto E; Rauscher FJ; Chen J
EMBO J; 2005 Sep; 24(18):3279-90. PubMed ID: 16107876
[TBL] [Abstract][Full Text] [Related]
11. UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HDM2 interaction in human fibroblasts.
Latonen L; Taya Y; Laiho M
Oncogene; 2001 Oct; 20(46):6784-93. PubMed ID: 11709713
[TBL] [Abstract][Full Text] [Related]
12. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.
Linares LK; Hengstermann A; Ciechanover A; Müller S; Scheffner M
Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12009-14. PubMed ID: 14507994
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of the hdm2-p53 interaction.
Böttger A; Böttger V; Garcia-Echeverria C; Chène P; Hochkeppel HK; Sampson W; Ang K; Howard SF; Picksley SM; Lane DP
J Mol Biol; 1997 Jun; 269(5):744-56. PubMed ID: 9223638
[TBL] [Abstract][Full Text] [Related]
14. Development of a binding assay for p53/HDM2 by using homogeneous time-resolved fluorescence.
Kane SA; Fleener CA; Zhang YS; Davis LJ; Musselman AL; Huang PS
Anal Biochem; 2000 Feb; 278(1):29-38. PubMed ID: 10640350
[TBL] [Abstract][Full Text] [Related]
15. Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects.
Ionov Y; Le X; Tunquist BJ; Sweetenham J; Sachs T; Ryder J; Johnson T; Lilly MB; Kraft AS
Anticancer Res; 2003; 23(1A):167-78. PubMed ID: 12680209
[TBL] [Abstract][Full Text] [Related]
16. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
17. Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells.
Chène P; Fuchs J; Carena I; Furet P; García-Echeverría C
FEBS Lett; 2002 Oct; 529(2-3):293-7. PubMed ID: 12372616
[TBL] [Abstract][Full Text] [Related]
18. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.
Chène P; Fuchs J; Bohn J; García-Echeverría C; Furet P; Fabbro D
J Mol Biol; 2000 May; 299(1):245-53. PubMed ID: 10860736
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
20. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage.
Joseph TW; Zaika A; Moll UM
FASEB J; 2003 Sep; 17(12):1622-30. PubMed ID: 12958168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
